Kamada Ltd. KMDA
8.13 USD +0.03 (+0.37%)
At closeNov 11, 2026, 4:00 PM EST
8.13 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
8.04 Day range 8.15
6.60 52-week range 9.35
- YTD
- +15.16%
- 1 year
- +15.16%
News
seekingalpha.com Kamada Ltd. (KMDA) Q3 2026 Earnings Call Transcript Kamada Ltd. (KMDA) Q3 2026 Earnings Call Transcript
zacks.com Kamada (KMDA) Surpasses Q3 Earnings Estimates Kamada (KMDA) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.09 per share a year ago.
benzinga.com Kamada Q3 2026 Earnings Call Transcript Kamada (NASDAQ:KMDA) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com Kamada Q3 EPS $0.14 Beats $0.13 Estimate, Sales $52.034M Miss $52.506M Estimate Kamada (NASDAQ:KMDA) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.13 by 7.69 percent. This is a 55.56 percent increase over earnings of $0.09 per…
benzinga.com Kamada Raises FY2026 Sales Guidance from $200.000M-$205.000M to $205.000M-$208.000M vs $202.960M Est Kamada (NASDAQ:KMDA) raises FY2026 sales outlook from $200.000 million-$205.000 million to $205.000 million-$208.000 million vs $202.960 million estimate.
globenewswire.com Kamada Reports Record-High First Nine Months 2026 Financial Results; Increases 2026 Annual Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2027 REHOVOT, Israel, and HOBOKEN, N.J., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for…
globenewswire.com Kamada Declares Cash Dividend of $0.14 Per Share; The Company Continues its Record-High Year REHOVOT, Israel and HOBOKEN, N.J., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd.
zacks.com Ahead of Kamada (KMDA) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics Evaluate the expected performance of Kamada (KMDA) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key…
globenewswire.com Kamada to Announce Third Quarter and Nine Months Ended September 30, 2026, Financial Results on November 9, 2026 REHOVOT, Israel and HOBOKEN, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd.
globenewswire.com Kamada Announces Participation in the Stifel 2026 Healthcare Conference and the Jefferies Global Healthcare Conference in London During November 2026 REHOVOT, Israel and HOBOKEN, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd.
benzinga.com Kamada Expands Biosimilar Portfolio With Commercial Launch Of Two Additional New Products In Israel, Adding To Existing Portfolio Of Two Products Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty…
globenewswire.com Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israel Company Expects Growing Biosimilar Product Portfolio, Commercialized in Israel and the MENA Region, to Generate Approximately $10 Million in Annual Revenue in 2028 and Approximately $20 Million-$25…
defenseworld.net Kamada Targets $205M Revenue as Plasma Therapies, Kedrab Demand Fuel Growth Kamada (NASDAQ: KMDA) outlined its growth strategy, product portfolio and financial outlook during a company presentation, emphasizing demand for specialty plasma-derived therapies and a plan to…
marketbeat.com Kamada Targets $205M Revenue as Plasma Therapies, Kedrab Demand Fuel Growth Kamada NASDAQ: KMDA outlined its growth strategy, product portfolio and financial outlook during a company presentation, emphasizing demand for specialty plasma-derived therapies and a plan to expand…
globenewswire.com CDC Highlights Significant Increase in U.S. Rabies Exposures and Anti-Rabies Immunoglobulin Utilization; Kamada Confirms Sufficient KedRAB® Supply to Meet Increased Demand U.S. Centers for Disease Control and Prevention (CDC) Reports a Significant Year-Over-Year Increase in Nationwide Rabies Exposures and Rabies Immunoglobulin Utilization KedRAB is One of Only Two…
globenewswire.com Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference REHOVOT, Israel, and HOBOKEN, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated…
globenewswire.com Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders REHOVOT, Israel and HOBOKEN, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (the “Company”) (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed…
globenewswire.com Kamada Declares Cash Dividend of $0.17 Per Share; The Company Reported Record-High Revenue and Profitability for First Six Months of 2026 Dividend to be Paid Consistent with the Company's Cash Dividend Policy Dividend to be Paid Consistent with the Company's Cash Dividend Policy
zacks.com Is Kamada (KMDA) a Solid Growth Stock? 3 Reasons to Think "Yes" Kamada (KMDA) possesses solid growth attributes, which could help it handily outperform the market.
zacks.com KMDA or PRTA: Which Is the Better Value Stock Right Now? Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Kamada (KMDA) and Prothena (PRTA). But which of these two companies is the best option for those looking for…
zacks.com Wall Street Analysts Think Kamada (KMDA) Could Surge 79.06%: Read This Before Placing a Bet The consensus price target hints at a 79.1% upside potential for Kamada (KMDA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate…
seekingalpha.com Kamada Ltd. (KMDA) Q2 2026 Earnings Call Transcript Kamada Ltd. (KMDA) Q2 2026 Earnings Call Transcript
zacks.com Kamada (KMDA) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates Although the revenue and EPS for Kamada (KMDA) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street…
zacks.com Kamada (KMDA) Q2 Earnings and Revenues Surpass Estimates Kamada (KMDA) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.13 per share a year ago.- benzinga.com Kamada Affirms FY2026 Sales Guidance of $200.000M-$205.000M vs $202.048M Est Kamada (NASDAQ:KMDA) affirms FY2026 sales outlook from $200.000 million-$205.000 million to $200.000 million-$205.000 million vs $202.048 million estimate.
benzinga.com Kamada Q2 EPS $0.16 Beats $0.12 Estimate, Sales $54.921M Beat $50.657M Estimate Kamada (NASDAQ:KMDA) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.12 by 33.33 percent. This is a 23.08 percent increase over earnings of $0.13 per…
benzinga.com Kamada Signs $50M Plasma Supply Agreement With Biopharma Partner Through Texas Centers, Commercial Sales Starting Q4 2026 Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty…- benzinga.com Kamada Highlights Results Of An Investigator-initiated Study Of Cytogam, The Company’s Cytomegalovirus Immune Globulin, In The Management Of Cytomegalovirus In Solid Organ Transplantation Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty…
benzinga.com Kamada Announces FDA Approval Of New In-House Rapid Fluorescent Focus Inhibition Test Laboratory Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty…
benzinga.com Kamada Q1 2026 Earnings Call: Complete Transcript 
benzinga.com Earnings Scheduled For May 13, 2026 
benzinga.com Kamada Affirms FY2026 Sales Guidance of $200.000M-$205.000M vs $201.581M Est Kamada (NASDAQ:KMDA) affirms FY2026 sales outlook from $200.000 million-$205.000 million to $200.000 million-$205.000 million vs $201.581 million estimate.- benzinga.com Kamada Q1 EPS $0.07 Misses $0.12 Estimate, Sales $45.240M Miss $46.722M Estimate Kamada (NASDAQ:KMDA) reported quarterly earnings of $0.07 per share which missed the analyst consensus estimate of $0.12 by 41.67 percent. This is unchanged from the same period last year. The…
benzinga.com Kamada Secures Israeli Tax Ruling On $0.25 Dividend, Allowing Reduced Withholding For Nasdaq Treaty Shareholders Kamada Ltd. (the "Company") (NASDAQ:KMDA, TASE: KMDA.TA))), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the…- benzinga.com Kamada Says FDA Approves Kamada Plasma's Collection Center In San Antonio San Antonio Center Cleared to Commence Commercial Sales of Normal Source PlasmaState of the Art Facility has Annual Collection Capacity of Approximately 50,000 Liters of Plasma and an Estimated…
- benzinga.com Earnings Scheduled For March 11, 2026
- benzinga.com Kamada Affirms FY2026 Sales Guidance of $200.000M-$205.000M Kamada (NASDAQ:KMDA) affirms FY2026 sales outlook from $200.000 million-$205.000 million to $200.000 million-$205.000 million.
- benzinga.com Kamada Q4 EPS $0.06 Misses $0.08 Estimate, Sales $44.678M Miss $45.422M Estimate Kamada (NASDAQ:KMDA) reported quarterly earnings of $0.06 per share which missed the analyst consensus estimate of $0.08 by 22.08 percent. This is a 14.29 percent decrease over earnings of $0.07 per…
benzinga.com What's Next: Kamada's Earnings Preview 
benzinga.com Earnings Scheduled For November 10, 2025 - benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com Earnings Scheduled For August 13, 2025 - benzinga.com Earnings Scheduled For May 14, 2025
- benzinga.com Earnings Scheduled For March 5, 2025
- benzinga.com Earnings Scheduled For November 13, 2024
- benzinga.com Earnings Scheduled For March 6, 2024 Companies Reporting Before The Bell • CTS (NYSE:CTS) is estimated to report quarterly earnings at $0.14 per share on revenue of $708.85 million.
- benzinga.com Earnings Scheduled For November 13, 2023 Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter.
- benzinga.com Why ParaZero Technologies Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Monday's Mid-Day Session Gainers ParaZero Technologies Ltd. (NASDAQ: PRZO) shares jumped 106% to $2.3901 after the company announced an Australian regulator approved first commercial drone flights in populated areas and near…
- benzinga.com Earnings Scheduled For May 24, 2023 Companies Reporting Before The Bell • Bank of Nova Scotia (NYSE:BNS) is estimated to report quarterly earnings at $1.78 per share on revenue of $8.09 billion.
- benzinga.com Earnings Scheduled For May 17, 2023 Companies Reporting Before The Bell • Wix.com (NASDAQ:WIX) is likely to report quarterly earnings at $0.14 per share on revenue of $369.35 million.